- Home
- BME vs ERAS Comparison
BME vs ERAS Comparison
Compare BME & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BME
- ERAS
- Stock Information
- Founded
- BME 2005
- ERAS 2018
- Country
- BME United States
- ERAS United States
- Employees
- BME N/A
- ERAS N/A
- Industry
- BME Trusts Except Educational Religious and Charitable
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- BME Finance
- ERAS Health Care
- Exchange
- BME Nasdaq
- ERAS Nasdaq
- Market Cap
- BME 462.3M
- ERAS 410.8M
- IPO Year
- BME N/A
- ERAS 2021
- Fundamental
- Price
- BME $36.05
- ERAS $1.33
- Analyst Decision
- BME
- ERAS Strong Buy
- Analyst Count
- BME 0
- ERAS 6
- Target Price
- BME N/A
- ERAS $4.83
- AVG Volume (30 Days)
- BME 34.0K
- ERAS 1.3M
- Earning Date
- BME 01-01-0001
- ERAS 05-20-2025
- Dividend Yield
- BME 6.26%
- ERAS N/A
- EPS Growth
- BME N/A
- ERAS N/A
- EPS
- BME 1.44
- ERAS N/A
- Revenue
- BME N/A
- ERAS N/A
- Revenue This Year
- BME N/A
- ERAS N/A
- Revenue Next Year
- BME N/A
- ERAS N/A
- P/E Ratio
- BME $28.37
- ERAS N/A
- Revenue Growth
- BME N/A
- ERAS N/A
- 52 Week Low
- BME $35.53
- ERAS $1.01
- 52 Week High
- BME $43.20
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- BME 41.88
- ERAS 48.02
- Support Level
- BME $36.11
- ERAS $1.37
- Resistance Level
- BME $36.82
- ERAS $1.53
- Average True Range (ATR)
- BME 0.50
- ERAS 0.13
- MACD
- BME 0.01
- ERAS -0.00
- Stochastic Oscillator
- BME 0.62
- ERAS 30.86
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.